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INJECTION FACILITY, AND POSSIBLE IMPLEMENTATION IN  
 
MASSACHUSETTS 
 
 
RYAN PERERA 
 
ABSTRACT 
 The impact of the opioid crisis has been worsening in recent years. Opioid-related 
overdose deaths in the United States have reached 9.0 per 100,000 people and in 
Massachusetts the number is even worse at 17.3 per 100,000. People who inject drugs 
(PWID) are at high risk of overdose death, of superficial and deep tissue bacterial 
infections, and of chronic viral infections such as human immunodeficiency virus (HIV) 
and hepatitis C virus (HCV), which can be transmitted through shared injection 
equipment. Although abstinence from substances is the best way to avoid these outcomes, 
the complicated nature of substance use disorder (SUD) means that not everyone will be 
able to stop substance use at any given time. The concept of harm reduction is based on 
engaging PWID who are not ready or able to stop substance use, to reduce the frequency 
of adverse outcomes. One intervention supported by harm reductionists is medically 
supervised infection facilities (SIFs), which are locations where PWID may inject 
substances under medical supervision. People are provided with clean equipment and are 
monitored post-injection so that medical intervention can be provided in case of an 
v 
 
overdose. Furthermore, people are able to access a variety of health services, including 
wound care, condom access, and referrals to SUD treatment.  
In 2003, Insite in Vancouver, Canada became North America’s first legally 
sanctioned SIF. Research conducted since its opening has shown many positive benefits. 
Insite has been credited with the prevention of overdose deaths and the encouragement of 
safer injection practices both inside and outside of the facility. In addition, the facility has 
been shown to be an effective bridge to addiction treatment, particularly among higher 
risk PWID. The presence of Insite has also been associated with a reduction in public 
injections. Furthermore, Insite does not appear to increase the number of people who are 
actively injecting, nor does it serve as a location for people who are injecting drugs for 
the first time. 
 Because of these benefits, there has been growing interest in establishing an SIF 
within the United States. Advocacy groups, including the Massachusetts Medical Society, 
have begun to press for one within Massachusetts. Moreover, the PWID community in 
Boston has expressed interest in taking advantage of the harm reduction benefits that an 
SIF can offer. Efforts to establish an SIF, however, face several barriers including state 
and federal drug laws and political opposition to such a facility. The stigma associated 
with SUD and the very idea of an SIF is an issue that must be addressed in order to bring 
this life saving tool to Massachusetts.  
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 1 
INTRODUCTION 
 
Opioid Use Disorder 
Substance use disorder (SUD) is a disease characterized by loss of control due to 
a drug or chemical and ongoing use of that substance in spite of negative consequences. 
Affected individuals may experience different stages: binge/intoxication, 
withdrawal/negative affect, and preoccupation/anticipation. During the binge/intoxication 
stage, the individual receives positive reinforcement as a result of using the drug. The 
withdrawal/negative affect stage is triggered when an individual with drug addiction 
consumes an inadequate amount of the drug, leading to negative reinforcement though 
symptoms such as chronic irritability, physical pain, and loss of motivation. The cravings 
that the individual has towards the drug are characterized as the 
preoccupation/anticipation stage. Together, these three stages make up the cycle of 
addiction and are associated with changes in the regulation of the brain reward function 
(Koob et al., 2014). 
Opioid use disorder is a type of substance use disorder that can be caused by a 
variety of legal and illicitly manufactured opioids. The first are prescription opioid pain 
relievers made legally by pharmaceutical companies, which can be used differently than 
prescribed or sold on the street. The second are counterfeit versions of legally produced 
pain pills, which are often created in overseas laboratories and filled with filler material. 
The third are illicit drugs like heroin, which is pharmacologically similar to morphine and 
other conventional pain medications, which are produced and obtained through illegal 
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means. The fourth category comprises highly potent illicit drugs, the most common of 
which is illicitly manufactured fentanyl (IMF) and its analogues. Fentanyl is a synthetic 
opioid that is 50% to 100% more potent than morphine, and the legally produced forms 
serve as valuable painkillers in clinical situations (Pergolizzi, LeQuang, Taylor, & Raffa, 
2017). On the other hand, IMF is produced in illegal laboratories and often contains 
analogues with variable potency. The variable potency serves to make it difficult for a 
person who consumes IMF to predict how the drug will affect them, and the evidence 
suggests that the growing use of IMF has led to an increase in the number of overdose 
fatalities (Daniulaityte, 2017).  
The United States Drug Enforcement Agency (DEA) considers controlled 
substances to be drugs and certain chemicals used to make drugs, that have the potential 
to develop physical or mental dependence. The DEA splits controlled substances into five 
groups, Schedule I through Schedule V. Schedule I drugs, like heroin, have no medical 
use but have a high potential for addiction. Schedule II through Schedule V drugs contain 
substances with medical use and have a decreasing risk of misuse, from Schedule II with 
the highest to Schedule V with the lowest. The use in clinical and research settings of 
Schedule I and II drugs, the drugs with the highest potential for misuse, is closely 
monitored and regulated by the DEA. Quotas are enforced on the amounts of these drugs 
that can be produced yearly in the United States, distribution must follow specific 
guidelines to make sure that only authorized individuals receive these substances, and 
detailed records are kept for their production and distribution to ensure that there is no 
diversion to illicit use or sales. One major difference between Schedule I and II drugs is 
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that Schedule I substances are banned from being used in medical situations (“Drugs of 
Abuse,” 2017). 
The introduction of illicitly manufactured fentanyl into the street-level supply of 
other substances is particularly dangerous because often the individual does not realize 
that the injection contains fentanyl. Frequently, fentanyl is mixed into the supply of a 
different drug, so when a person who uses drugs consumes his or her drug of choice, the 
individual is unknowingly also consuming fentanyl. Prior research suggests that a 
majority of people who use drugs and who tested positive for fentanyl were unaware that 
they were using fentanyl (Amlani et al., 2015; Macmadu, Carroll, Hadland, Green, & 
Marshall, 2017). 
In mice models, heroin contaminated with fentanyl resulted in a strong 
potentiation of brain hypoxia that lasted for a drastically longer duration than mice that 
were injected with only heroin. The mixture caused prolonged motor inhibition, with 
strongly decreased brain and body temperatures, similar to a state of deep sedation. This 
state can increase the risk of asphyxiation due to the inability to control respiratory 
function (Solis, Cameron-Burr, & Kivatkin, 2017). Furthermore, IMF is significantly 
cheaper than heroin: one kilogram of heroin costs about $65,000 whereas the same 
amount of IMF is about $3,500. This cost difference produces a financial incentive for 
drug dealers to mix fentanyl into their supply of heroin in order to increase the potency of 
a smaller amount of heroin. In addition, IMF has also been found to contribute to 
fatalities when mixed with drugs besides illicit opioids, such as ecstasy 
(methylenedioxymethamphetamine) and counterfeit Xanax (alprazolam). In many of 
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these fatalities, it appears that the deceased individuals were not aware that they were 
consuming IMF (Frank & Pollack, 2017). Synthetic opioids, like IMF, have recently even 
started to be responsible for more deaths than heroin (Figure 1) 
 
Figure 1: The number of deaths in the United States from various drug classes. This 
graph shows that the fatalities from most drugs has stayed relatively constant while the 
fatalities due to synthetic opioids, like illicit fentanyl, has dramatically increased since 
December, 2014. Source: (“Products – Vital Statistics Rapid Release – Provisional Drug 
Overdose Death Counts,” 2018). 
 
Despite an increase in the availability of treatment services, the mortality rate in 
Massachusetts from opioid-related overdose deaths increased at a faster pace than the 
national average from 2010 to 2014 (Figure 2). In 2014, the mortality rate reached 17.3 
overdose deaths per 100,000 in Massachusetts compared with the national average of 9.0 
deaths per 100,000. Furthermore, fentanyl has quickly become involved in the majority 
of the opioid-related overdose deaths (Figure 3), and it was involved in nearly 70% of 
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overdose deaths in Massachusetts during the first quarter of 2016, up from about 30% in 
the third quarter of 2014 (“Opioid Use Disorder in Massachusetts,” 2016). 
 
Figure 2: Opioid-related drug overdose deaths per 100,000 persons, in Massachusetts 
and the United States (1999-2014). This graph shows how the mortality rates have been 
increasing in both the United States and Massachusetts. Since 2010, the mortality rate in 
Massachusetts has increased at a much greater rate than the national average Source: 
(“Opioid Use Disorder in Massachusetts,” 2016). 
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Figure 3: Presence of various substances in opioid-related overdose deaths in 
Massachusetts (2014-2016). This graph shows that fentanyl is increasingly present in the 
setting of opioid-related death, while other substances have remained stable or decreased. 
Source: (“Opioid Use Disorder in Massachusetts,” 2016). 
 
Harm Reduction Programs  
Harm reduction programs are systems developed to reduce the risk of adverse 
outcomes as a result of drug use. The concept of harm reduction originated in Europe; 
later, in North America, harm reduction was considered as an alternative to law 
enforcement for reducing the transmission of human immunodeficiency virus (HIV), the 
virus responsible for acquired immune deficiency syndrome (AIDS), and other diseases 
in people who inject drugs (PWID). Even though the primary goal of addiction treatment 
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is to help the person enter a long-term stable recovery free from substance use, harm 
reduction acknowledges that each person has different circumstances surrounding their 
disease, and at any given time there will be a population of people who are not ready or 
not able to stop drug use completely. Harm reduction seeks to engage with those people 
who are actively using drugs in order to reduce their risks of infection and overdose as 
well as their societal and medical marginalization. Harm reductionists prefer to look at 
people who inject drugs as a community with distinct social and medical needs rather 
than a criminal element in society (Roe, 2005). Since harm reduction does not require 
abstinence from people in order to deliver them care, opponents of harm reduction argue 
that instead of helping people, harm reductionists are enabling future drug use. Advocates 
of abstinence-only treatment contend that the fear of negative outcomes, like overdose 
and severe infections, serves as a strong motivation for people to quit, and the efforts of 
harm reductionists serve to remove that motivation (MacCoun, 2013).  
However, based on the reasoning presented by abstinence-only advocates, the 
observed increase in yearly opioid-related overdose deaths should have served to 
decrease the amount of people using heroin. As people became aware of the increasing 
death toll, they would fear for their lives and be further motivated to quit their substance 
use. However, the 2016 National Survey of Drug Use and Health found that the 
percentage of people in the United States who were using heroin had increased in recent 
years (Ahrnsbrack, 2016). The increase in mortality did not produce the reduction in 
substance use that would be expected if fear of adverse outcomes was all that was needed 
to achieve abstinence.  
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People who inject drugs have a much higher risk of contracting chronic viral 
infections such as HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV), as a result 
of risk behavior that includes sharing of used needles. In 2011, the rate of HIV among 
people who had injected drugs in their lifetime was 2,147 per 100,000 and the rate of who 
were HCV antibody positive, indicating that they had been exposed to HCV, was 43,126 
per 100,000 (Lansky et al. 2014). In response to the HIV epidemic of the 1980’s and 
1990’s and the current opioid crisis, a variety of harm reduction strategies have been 
evaluated, including needles exchanges, counseling, post-injection monitoring, and 
supervised injection facilities.  
The conflict between those who advocate for harm reduction and those who 
support abstinence-only treatment can be seen in the history of needle exchanges in the 
United States. Needle exchange is a service that distribute sterile needles and other 
equipment with the goal of reducing the spread of infection among people who inject 
drugs. In 1988, the United States government banned the use of federal funds for needle 
exchange, and nearly two dozen states took the added step of banning the possession or 
distribution of needles without a prescription.  
This ban became a significant public health issue when a small rural community 
in Scott County, Indiana, a state with a ban on non-prescription needles, experienced a 
surge in the number of new HIV infections. In January 2015, the Indiana State 
Department of Health began investigating 11 new HIV infections within this community, 
which had previously only experienced 5 new HIV infections from 2004 to 2013. All of 
the people with new HIV infections reported recently injecting the prescription opioid 
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oxymorphone and sharing used syringes (Peters et al., 2016). Indiana’s governor at the 
time, Mike Pence, had previously stated that he was morally opposed to needle 
exchanges on the grounds that they support drug misuse. However, the distribution of 
clean needles is an evidence based practice that has been found to be associated with a 
reduction of HIV transmission and high-risk injection activities, such as the sharing or re-
use of needles (Fernandes et al., 2017). As more new HIV cases were discovered in Scott 
County, law enforcement, public health officials, and members of the community started 
pressuring Governor Pence to allow the distribution of clean needles. On March 25, 2015, 
more than two months after the outbreak was first noticed, the governor signed an 
executive order allowing for clean syringes to be distributed in Scott County. Over the 
following months, this effort, along with substance use disorder treatment and outreach, 
contributed to a dramatic decrease in the rate of new HIV infections (Figure 4). Although 
these measures did eventually end the crisis, 181 people were newly diagnosed with HIV 
from November 18, 2014 to November 1, 2015 (Twohey, 2016).  
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Figure 4: History of the outbreak of HIV infection in southeastern Indiana. (A) This 
graph tracks the cumulative HIV diagnoses that were associated with the injection of 
oxymorphone and the public health response from November 18, 2014 to November 1, 
2015. DIS denotes disease intervention specialist. “Incident command established” 
indicates that the state’s health department used a standardized approach to the command, 
control, and coordination of the emergency response. (B) This bar chart shows the HIV 
infections that were associated with injection of oxymorphone according to the week of 
study. HIV diagnoses peaked during March and April of 2015. Source: (Peters et al., 
2016) 
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There are three primary medication options for the treatment of opioid use 
disorder: methadone, buprenorphine, and naltrexone. Methadone is a long-acting full 
opioid agonist that can reduce the cycles of intense euphoria to withdrawal that is found 
in opioid use disorders. Buprenorphine is a partial opioid agonist that can be administered 
in a general medical setting unlike methadone which is limited to federally regulated 
methadone programs. Naltrexone is an opioid antagonist that works by reducing a 
person’s urge to use substances and by interfering with their desire to continue use if they 
do consume a substance. Naltrexone is not only effective at treating opioid use disorder 
but can also be used for treatment of alcohol use disorder (American Academy of 
Pediatrics Committee on Substance Use and Prevention, 2016). 
Needle exchange programs (NEPs) attempt to reduce the prevalence of chronic 
viral infections within the community of people who inject drugs by providing 
opportunities to access clean injection equipment. The expansion of NEPs in the United 
States has been associated with a reduction of HIV prevalence among people who inject 
drugs by approximately 10% per year during the years 2001- 2005. In addition, many 
NEPs offer a range of other health and social services to participants, including condoms, 
health education, and referrals for treatment (Des Jarlais, McKnight, Goldblatt, & 
Purchase, 2009). According to the North American Syringe Exchange Network 
(NASEN), as of May 2015, there were 228 syringe exchange facilities in the United 
States. These programs are located in 35 states, as well as the District of Columbia, 
Puerto Rico, and the Indian Nations. Massachusetts was home to 10 of these programs. 
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(“North American Syringe Exchange Network Directory of Syringe Exchange 
Programs,” n.d.) 
In addition to NEPs, pharmacies in Massachusetts are allowed to sell syringes 
without a prescription. In one study, about 87% of respondents from Massachusetts 
reported buying syringes from a pharmacy. This arrangement provides a resource of 
clean syringes for people who inject drugs but who are not able to or choose not to take 
advantage of needle exchange programs. This is particularly important given that 
pharmacies are much more widespread than NEPs and tend to have longer operating 
hours (Zaller et al., 2012). 
Overdose education and naloxone distribution (OEND) programs are a type of 
harm reduction that aims to reduce overdose deaths through educating people who may 
experience or witness an overdose on how to prevent, recognize, and respond to an 
overdose. Massachusetts began implementing these programs in 2006. Enrollees were 
taught necessary skills to deal with an overdose until professional medical help arrived. 
In addition, enrollees were taught how to use intranasal naloxone, an opioid antagonist 
that counteracts opioid overdose. Between 2006 and 2009, there were 2912 individuals 
trained through OEND programs in Massachusetts. Once the rates of overdose deaths 
during this time period were controlled for other contributing factors, such as the 
demographics, economic status, and the amount of resources available to PWID, it was 
found that communities that had participated in these programs had a significant 
reduction in opioid-related overdose deaths. In communities with 1 to 100 enrollees per 
100,000 people, there was a 27% reduction in overdose mortality, and in communities 
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that had over 100 enrollees per 100,000 people, there was a 46% reduction in overdose 
mortality (Walley et al., 2013). 
A relatively new addition to the harm reduction tools in Massachusetts is the 
Supportive Place for Observation and Treatment (SPOT) run by the Boston Healthcare 
for the Homeless Program (BHCHP). SPOT offers refuge and medical monitoring for 
people who are overly-sedated due to substance use and are in need of a safe location 
where they can have fast access to medical assistance. Many of the people who use SPOT 
would otherwise be forced to find shelter in an alleyway or public bathroom, where if an 
overdose occurs they will be unable to receive immediate treatment (“Spot | Boston 
Health Care for the Homeless Program,” n.d.). SPOT does not allow people to use 
substances in their facility, but if a person arrives after consumption, the on-site medical 
professionals are prepared to administer naloxone and supplemental oxygen in the event 
of an overdose. The goal of this facility is to directly reduce the number of adverse 
outcomes due to drug overdose. After the opening of SPOT in April 2016, there was a 
28% decrease in the numbers of overly-sedated people in public within a 500-meter area 
of the facility, demonstrating the effectiveness of moving at-risk individuals to a safer 
location (León et al., 2018). 
 
Supervised Injection Facilities (SIFs) 
The current harm rejection efforts in the United States have been beneficial but 
they have not been enough to turn the tide against the opioid epidemic. There is a need 
for more solutions to the current opioid crisis. Supervised injection facilities (SIFs) are 
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clinics in which PWID are given a safe space and sterile tools to inject drugs and are 
monitored post-injection in case intervention is necessary in the event of an overdose. 
SIFs are one such solution that has been implemented in other countries; however 
political, legal, and social barriers have thus far prevented the official establishment of an 
SIF in the United States (Irwin et al., 2017). The only SIF located in North America is the 
Insite clinic located in the Downtown Eastside (DTES) community of Vancouver, 
Canada. The facility has an average of 514 injection room visits a day and is connected to 
a detox facility and temporary shelter for PWID (“Insite User Statistics – Vancouver 
Coastal Health,” n.d.). This clinic has been the subject of dozens of scientific peer-
reviewed studies since it opened in 2003 (Jozaghi & Andresen, 2013). 
 In the United States SIFs are being considered by the cities of Seattle and 
Philadelphia as well as the states of New York and California as a possible tool to fight 
against the infection and mortality rates of people who inject drugs. Massachusetts has 
recently been experiencing a push toward implementing such a facility. The 
Massachusetts Medical Society (MMS) has endorsed implementation of a pilot SIF 
program. However, state and federal drug laws, political and local community opposition, 
and questions surrounding police response have served to create barriers toward the 
development of a legal SIF.  
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Specific Aims 
The worsening nature of the opioid crisis in Massachusetts requires new solutions to 
reduce morbidity and mortality. Medically supervised injection facilities (SIFs), like 
Insite, can provide harm reduction benefits that can reduce the impact of the crisis. 
The specific aims of this thesis are: 
1. To review the literature surrounding the impact of Insite on the Downtown 
Eastside (DTES) community of Vancouver, Canada. 
2. To investigate the factors at play in the debate over establishing a pilot SIF 
program in Massachusetts. 
The information provided from this study can serve to inform on the benefits of SIFs as 
well as the opportunities and barriers to establishing a SIF in Massachusetts. In the next 
section, the impact that Insite has had on the community will be explored across six 
points of concern. In the last section, the support and opposition for a Massachusetts SIF 
will be reviewed. 
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LITERATURE REVIEW 
THE IMPACT OF INSITE ON THE DOWNTOWN EASTSIDE COMMUNITY 
OF VANCOUVER 
 
In this thesis, the focus is on investigating the impact of Insite on the Downtown 
Eastside (DTES) community of Vancouver, Canada. A review of the research about 
Insite was organized around answering the set of questions listed in Table 1. The answers 
to these questions were then used to consider whether Massachusetts would benefit from 
establishing its own SIF. 
Table 1: Points of Concern When Evaluating the Impact of Insite  
Does Insite reduce the risk of injection-related harms? 
Does Insite promote treatment for substance use disorder? 
How effective are the non-drug-related social services offered at Insite? 
What is the effect of Insite on the greater community? 
Does Insite provide safety for vulnerable groups? 
Does Insite encourage more drug use and first-time use? 
Insite is a supervised injection facility located in Vancouver, Canada. Since opening in 
2003, dozens of studies were conducted on this facility, many of which sought to answer 
one of the six questions listed above. 
 
Does Insite Reduce The Risk of Injection Related Harms? 
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One of the main goals of Insite is to move people away from unsafe injecting 
environments, like street corners or public bathrooms, where they are less likely to 
receive timely medical attention if they experience an overdose. Availability of prompt 
medical attention is particularly important given presence of illicitly manufactured in the 
heroin and other drug supply, because an overdose due to IMF can progress over seconds 
to minutes. When the United States Centers for Disease Control and Prevention (CDC) 
carried out an investigation of the segment of deaths from opioids, they found that 36% 
of those deaths had an overdose that occurred within minutes and that 90% of the 
fentanyl overdose decedents were pulseless on arrival of emergency medical services 
(Somerville, 2017). The aim of SIFs is to remove this delay in receiving medical help, 
and the popularity of Insite has proven that the PWID community will attend such a 
facility. Since Insite opened in 2003, there have been more than 3.6 million supervised 
injections and 6,440 overdose interventions without any deaths (“Insite User Statistics – 
Vancouver Coastal Health,” n.d.).  
In an attempt to quantify the number of overdose deaths prevented each year, 
Andreson and Boyd (2010) looked at the number of potentially fatal overdoses that 
occurred at Insite and compared the value with the overdoses that occurred within DTES. 
Due to the lack of reliable data on the rate of overdose in DTES outside of Insite, the rate 
of overdose within Insite, 1.3 overdoses per 1000 injections, was used to also represent 
the rate of overdose in DTES. Potentially fatal overdoses were defined conservatively as 
any overdose in which the person stops breathing. The rate of such overdoses was again 
taken from Insite where 16.4% of overdoses reached this definition of being potentially 
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fatal. Based on these numbers, together with the 236,520 yearly injections at Insite and 
the 4,565,000 estimated yearly injections in DTES, the number of potentially fatal yearly 
overdoses was 50 at Insite and 973 in DTES. Because the number of fatal drug overdoses 
in Vancouver is about 50 per year, and since DTES is home to approximately 42% of the 
PWID population in Vancouver, it was estimated that DTES experiences 21 fatal drug 
overdoses per year, at a rate of 2.16% of all potentially fatal overdoses. The application 
of this rate to the 50 potentially fatal overdoses at Insite, showed that 1.08 overdose 
deaths per year have been averted because of Insite (Andreson & Boyd, 2010). 
Another study used a similar methodology but with a less strict definition for 
potentially fatal overdose, defined as any overdose event that required the administration 
of naloxone, a 911 call, and/or an ambulance (Milloy, Kerr, Tyndall, Montaner, & Wood, 
2008). Because of the wide range of non-fatal overdose rates that are reported in the 
literature, investigators used a sensitivity analysis with the non-fatal overdose rates of 50, 
200, and 300 per 1,000 person years. Using these numbers, they estimated that a range of 
1.9 to 11.7 deaths were prevented each year as a result of Insite (Milloy et al., 2008). A 
separate study found that the fatal overdose rate decreased by 35% for city blocks within 
500 meters of Insite, whereas the fatal overdose rate in the rest of the city only decreased 
by 9.3%, providing further evidence that the presence of a SIF leads to a reduction of 
overdose deaths (Marshall, Milloy, Wood, Montaner, & Kerr, 2011). 
Would people who attend Insite otherwise be engaging in risky behaviors if they 
did not have the option to use an SIF? It is possible that the people who go to Insite 
possess better health awareness or resources than the general PWID community, and 
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therefore engage in riskier behavior less often. If this is the case, the benefit of having an 
SIF in a community would be less than it actually appears. Therefore, when the amount 
of harm reduction by Insite is evaluated, it is also important to evaluate the characteristics 
and habits of PWID who attend this facility. In a survey of a cohort of PWID who 
attended Insite, daily SIF use was found to be associated with homelessness. This is an 
encouraging finding because homeless people are more likely to inject in public, and their 
attendance at Insite allows them to replace a risky public injection with a safe, supervised 
one. Furthermore, daily attendance at Insite is associated with daily heroin and daily 
cocaine use, which are factors that are linked to elevated rates of HIV infections among 
PWID in Vancouver (Wood et al., 2006). Needle and equipment sharing among PWID 
have been frequently linked to HIV outbreaks around the world (Zule et al., 2018). 
Because Insite provides each individual with personal injection equipment, the site serves 
to block the potential spread of HIV from injections that occurred at this facility.  
In addition to providing medical interventions in the case of an overdose and 
preventing the use of shared injection equipment, Insite has also made the process of 
injecting drugs safer. In a cohort of 1082 individuals recruited from December 2003 to 
September 2005, 809 (75%) reported that since attending Insite, they had changed their 
injection habits (Petrar et al., 2007). Out of these 809 people, a majority reported that 
they were less rushed while injecting, injected outdoors less often, disposed of equipment 
in a safer way, had an easier time finding a vein, and used clean water while injecting 
more often. There were also reports of cleaning the injection site more often, reusing 
injection equipment less often, and being able to inject without the assistance of others 
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(Figure 5). These positive changes in injection habits help to reduce the impact on the 
public of public injections and reduce the infectious risks of injection (Petrar et al. 2007). 
 
 
Figure 5. PWID responses to survey question: In what way has Insite changed your 
injection behaviors? This bar chart shows the number of responses to this question from 
809 individuals who reported that Insite had changed their injecting behavior. Insite is the 
supervised injection facility in Vancouver Canada. PWID stands for people who inject 
drugs. Source (Petrar et al., 2007) 
 
The Petrar et al. (2007) survey also looked for reasons why a PWID would choose 
not to use an SIF. The most frequently reported reasons were distance from the SIF, 
difficulties stemming from the operating hours of the SIF, waiting times to access an 
injection site, and police presence around the SIF. Efforts made to alleviate these 
concerns could prove helpful in increasing the number of people reached by SIFs (Petrar 
et al. 2007). 
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Does Insite Promote Treatment for Substance Use Disorder? 
 Evidence-based substance use disorder treatment is recognized as the primary 
avenue to help people overcome SUD-related problems. As a result, several studies have 
evaluated whether attendance at Insite is associated with the initiation of detox and long-
term addiction treatment. One study examined the rates of use of detoxification services 
after the opening of Insite compared with the prior year (Wood, Tyndall, Zhang, 
Montaner, & Kerr, 2007). The study found that the opening of the SIF was associated 
with a greater than 30% increase in detox use. Furthermore, use of detoxification services 
was independently associated with the initiation of methadone and other forms of 
addiction treatment (Wood, Tyndall, Zhang, Montaner, & Kerr, 2007). Detox can serve 
as a stepping stone to get people into long-term addiction treatment. The increase in the 
number of referrals to detoxification services can be attributed to how SIFs engage 
PWID. PWID are normally medically marginalized and difficult to engage. By attending 
a SIF, these people interact with medical professionals and develop their connection to 
the health care system (Wood, Tyndall, Zhang, Montaner, & Kerr, 2007). A similar 
increase can also be seen with needle exchanges, and it appears that any program that can 
place PWID in contact with medical professionals can serve as an important bridge to 
addiction treatment (Strathdee et al., 1999). 
Another study further supports the role of SIFs in getting people into treatment 
(DeBeck et al., 2011). Among a cohort of attendees at Insite from December 2003 to June 
2006, using the SIF on a regular basis and having contact with on-site counselors were 
positively associated with entry into addiction treatment programs. Moreover, entry into 
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addiction treatment programs was positively associated with cessation of injection drug 
use. This further supports the theory that SIFs attract people who would normally not be 
engaged in health care and, as a result, give them access to services. However, one 
notable exception was that Aboriginal people were less likely to enter addiction services 
and this highlights the need for SIFs to find innovative and culturally sensitive ways to 
engage this population (DeBeck et al., 2011). 
 In 2007, Insite opened its own on-site detoxification service named Onsite. Onsite 
offers 12 beds for stays from one to two weeks, and post-detox patients are given access 
to transitional housing. This detox service has no restrictions on substance use prior to 
detox. Onsite has proved popular, with over 2800 intakes since opening (Gaddis et al.).  
A retrospective cohort study of over 1300 PWID in Vancouver was carried out 
over a 25-month period, from November 1, 2010, to December 31, 2012. The results 
found that more than 10% of the participants reported accessing on-site detoxification 
services at a SIF over a median follow-up of 17 months. When the sample was restricted 
to people who had recently used an SIF, the percentage increased to 23.7% accessing on-
site detox. Furthermore, use of on-site detoxification services was associated with people 
who reported public injection, binge injection, and recent overdose. Detoxification 
services that are co-located with a SIF can be effective in engaging high-risk and 
marginalized PWID (Gaddis et al.). 
 
How Effective Are the Non-Drug Related Social Services Offered at Insite? 
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Although unsafe injecting practices play a major role in spreading HIV within the 
PWID community, high risk sexual practices are also a common source of HIV 
transmission. In order to reduce the spread of HIV and other sexually transmitted 
infections (STIs), Insite provides easy access to condoms. A variety of condoms are made 
available and can be picked up prior to or after an injection. Furthermore, the nurses at 
Insite, who monitor the injections at this facility also provide safe-sex education, 
counseling about condom use, and referrals to health services. A study of 1090 PWID 
who attended Insite from December 2003 to December 2005, examined how Insite 
affected the rates of condom use (Marshall et al., 2009). Participants were asked to state 
whether they had sexual intercourse with regular (relationship longer than 3 months) or 
casual (relationship for less than 3 months) partners in the past 6 months. They were also 
asked about how often they used condoms, with a response of 100% of the time being 
defined as “consistent” condom use and anything less being defined as “inconsistent” 
condom use. Initially, it was found that 25.3% of the people with regular partners and 
61.6% with casual partners reported consistent condom use. After two years consistent 
condom use increased to 32.9% for those with regular partners and to 69.8% for those 
with casual partners (Marshall et al. 2009). These findings suggest that the availability of 
condoms and sexual health services offered at Insite are able to encourage safer sex 
among PWID. 
PWID often rely heavily on emergency medical care and inpatient treatment over 
outpatient care (French, McGeary, Chitwood, & McCoy, 2000). This can be attributed to 
a tendency among PWID to postpone treatment. Costs of treatment, stigma and 
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discrimination associated with their status as PWID, and fear of criminal penalties are all 
barriers to care for PWID and these issues serve to make them a medically underserved 
and marginalized population (Small, Wood, Lloyd-Smith, Tyndall, & Kerr, 2008). A 
primary source of morbidity among PWID are cutaneous injection-related infections 
(CIRI), such as abscesses and cellulitis. The nurses at Insite offer primary medical care, 
including treatment for CIRI, and have been effective in engaging individuals in care. 
Among a cohort of 1080 PWID, 296 individuals (27%) had received CIRI care from a 
nurse at Insite; independent predictors for accessing CIRI care were female sex, unstable 
housing, and daily heroin injection (Lloyd-Smith et al., 2009). PWID who have used 
Insite for primary medical care emphasize the experience and nonjudgmental manner of 
Insite nurses who work with people with SUD. Their care did not contain the 
discrimination PWID have encountered in more conventional settings. In addition, Insite, 
which is open 7 days a week for 18 hours a day, provides a flexible schedule for people 
to come in for care. Furthermore, patients stated that they received counselling on how to 
treat emerging infections as well as referrals for outside services. All of these factors 
contribute to reducing the barriers that are faced by PWID when it comes to medical care 
and could reduce the reliance on emergency and inpatient care among this population 
(Small et al., 2008). 
 
What Is the Effect of Insite on the Greater Community? 
The addition of Insite to the community has also had a positive effect on reducing 
the public nuisance derived from public injection drug use. Figure 6 summarizes the 
 25 
results from a study looking at public nuisance 6 weeks before the opening of Insite to 12 
weeks after the opening (Wood et al., 2004). The study found statistically significant 
reductions in public injection drug use, publicly discarded syringes, and injection-related 
litter after the SIF opening. These reductions were independent of law enforcement 
activity and changes in rainfall, two factors that were theorized to affect injection 
activity. In addition, there was no change in the number of drug dealers in the vicinity of 
the facility, despite the concerns that an SIF would attract them to the local area (Wood et 
al, 2004). 
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Figure 6. The daily average of SIF use, public injection drug use, publicly discarded 
syringes, and injection-related litter counted 6 weeks before and 12 weeks after Insite 
opened. These graphs show that use of the SIF is positively correlated with a reduction in 
public injection and waste associated with drug use. Source: (Wood et al., 2004). 
 
Another concern that came with the opening of Insite was that there would be an 
associated rise in drug-related crimes in the area around the SIF. One study compared the 
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number of arrests for crimes that are attributed to a concentrated drug scene (drug 
trafficking, assaults, robberies, and vehicle break-ins and thefts) in the year before and 
the year after the opening of Insite (Wood, Tyndall, Lai, Montaner, & Kerr, 2006). It was 
found that although the rates of drug trafficking, assaults, and robberies did not change, 
the number of vehicle break-ins and theft significantly decreased. Because these numbers 
are based on arrests, they could be subject to changes in policing that occurred over the 
time period of the study. Regardless, there does not seem to be any evidence to suggest 
that the opening of an SIF is also linked to a marked increase in drug-related crimes 
(Wood, Tyndall, Lai, Montaner, & Kerr, 2006). 
 
Does Insite Provide Safety for Vulnerable Groups? 
The illicit and unregulated nature of street drugs frequently leads to the 
involvement of violence. Women experience high rates of victimization within this 
environment. HIV prevalence was found to be higher among women who report to have 
experienced sexual violence (Braitstein et al., 2003). Women tend to be placed in 
subordinate roles forcing them to become dependent on others, preventing them from 
being able to control their substance use (Fairbairn, Small, Shannon, Wood, & Kerr, 
2008). In addition, women who inject drugs are more likely to engage in transactional 
sex, the exchange of sex for money or drugs, than their male counterparts. In a study of 
women who inject drugs in New York City, 31% reported transactional sex in the last 12 
months. Women who are involved in transactional sex face difficulties negotiating 
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condom use and habits which results in a higher risk of HIV infection (Walters, Reilly, 
Neagus, & Braunstein, 2017). 
In a set of interviews of 25 women who attended Insite, the role of the SIF was 
examined in the context of this environment (Fairbairn, Small, Shannon, Wood, & Kerr, 
2008). Insite was seen as a refuge from the risk of violence that comes from preparing 
and using substances on the streets. Women at Insite were given more control over their 
substance use, increasing their power at the point of consumption. Drug use among 
intimate partners often has an unequal power dynamic that forces women into a 
dependent role in which they cannot exert complete control over their drug use and 
sexual practices. By providing an alternate and safe environment for injection, Insite was 
able to help these women reduce the risks that came from injecting with a partner 
(Fairbairn, Small, Shannon, Wood, & Kerr, 2008).  
Accidental drug overdose is the leading cause of death among young people who 
live or work on the street. This marginalized population experiences unstable housing and 
lacks safe locations to inject, forcing them to rely on public injections that are prone to 
being rushed or lacking in sterile equipment. In a study of actively drug-injecting street 
youth, 42% reported using the SIF at least once (Hadland et al., 2014). When not using 
the SIF, more than one-third reported public injections. Furthermore, high-risk activities, 
such as daily heroin use, daily cocaine use, daily crystal meth use, or visiting a crack 
house or shooting gallery, were all associated with increased likelihood to use a SIF. This 
suggests that Insite has been effective in engaging the most at-risk members of 
Vancouver’s street youth with medical support (Hadland et al., 2014). 
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Does Insite Encourage More Drug Use and First Time Use? 
A concern about Insite and SIFs in general is that these facilities will attract 
people who want to experience their first injection of an illicit substance. Although Insite 
officially does not allow first-time injection, it is still a possibility that some people might 
attempt to do so. A survey of people who attended Insite from December 2003 to October 
2005 was used to find the rate at which people go to Insite for their first injection (Kerr et 
al. 2007). Of the 1065 participants, only 1 admitted to having their first-time use at a SIF 
(Table 2). Most reported a long history of substance use with a median of 15.9 years of 
injection. Even when combining the rate at which people initiate injection drug use at 
Insite with the number of people attending Insite who had recently initiated injection, the 
rate of recent injection initiation at Insite was still lower than the estimated background 
level of injection initiation. Insite does not appear to prompt an increase in the number of 
PWID in its community (Kerr et al. 2007). 
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Table 2: Circumstances of First Time Drug Use Among Insite Users (2003-2005) 
 
This table shows that out of 1065 respondents, only one reported using a supervised 
injection facility (SIF) to initiate injection drug use. In comparison, usage of a borrowed 
syringe and receiving assistance with injection during first time use, high-risk activities 
that are common among first time users was also recorded. Because Insite bans syringe 
borrowing and assisted injection, there might be a benefit to allowing people who want to 
initiate injection drug use to do so at Insite. Insite is the SIF in Vancouver, Canada. Table 
taken from (Kerr et al., 2007). 
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Another study examined substance use habits in the year before and the year after 
the opening of Insite (Kerr at al., 2006). As Table 3 shows, there were no substantial 
changes in rates of relapse to injection drug use, cessation of injection drug use, starting 
binge drug use, smoking crack cocaine, stopping methadone therapy, and ending 
methadone therapy. The rates of relapse to binge drug use decreased, but at the same 
time, the rates of initiation of smoking crack cocaine increased. Since smoking of 
substances is banned at Insite, it appears unlikely that Insite was responsible for the 
increase in the initiation of smoking crack cocaine. These findings suggest that the 
presence of an SIF does not encourage riskier or negative substance use habits. (Kerr et 
al. 2006)
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Table 3: Changes in Drug Use Among Injecting Drug Users in Vancouver in One-Year 
Period Before and After the Opening of Insite.  
 
This table shows the changes in drug use before and after the opening of Insite. Only 
initiation of binge drug use (decreased) and the smoking of crack cocaine (increased) 
changed significantly between the two time periods. Values are expressed as numbers 
(percentages) of participants unless stated otherwise. Denominators vary because only 
some individuals were eligible for each change considered. Insite is the supervised 
injection facility located in Vancouver, Canada; n = 674 (before); n = 700 (after). Taken 
from (Kerr et al. 2006).  
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COULD MASSACHUSETTS HAVE ITS OWN SIF? 
 
Although Insite has been able to attract a large number of PWID to its facility, it 
is not a given that an SIF in Massachusetts would experience similar levels of popularity. 
One study surveyed PWID who used Boston’s needle exchange program to determine 
interest in using a SIF (León, Cardoso, Mackin, Bock, & Gaeta, 2017). This study found 
that 91.4% of respondent reported willingness to use a SIF. Furthermore, interest in using 
an SIF was positively associated with public injection, use of heroin as main substance, 
history of seeking treatment for SUD, current desire for SUD treatment, prior knowledge 
of SIF, Hispanic ethnicity, frequent NEP use, HCV diagnosis, at least one chronic 
medical diagnosis, and comorbid medical and mental health diagnoses (León, Cardoso, 
Mackin, Bock, & Gaeta, 2017). All of these subpopulations within the PWID community 
would benefit from the increased access to medical care offered at a SIF. 
There is also evidence to suggest that this initial interest will translate into 
participation at a SIF after opening. A survey of PWID in Vancouver prior to the opening 
of Insite asked the participants whether they would be willing to use a SIF and followed 
up with participants after the opening to see if they had used the facility (DeBeck et al. 
2012). Among participants who endorsed willingness to use a SIF, 72% reported 
attending Insite. Thus, initial willingness to use an SIF was independently associated with 
eventual attendance at Insite. Even among those who initially did not express interest, a 
majority (54%) later reported using Insite. (DeBeck et al. 2012). These findings are the 
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basis for believing that the SIF willingness study conducted in Massachusetts could 
predict a large attendance if a SIF is established.  
There is at least one confirmed case of an “underground” SIF operating within the 
United States, which has been operating since September 2014 (Davidson, Lopez, & 
Kral, 2018). This facility was developed by a social service agency that, after realizing 
people were using the agency’s bathroom to inject drugs, wanted to develop a safe 
alternative for those individuals. From September 2014 to October 2017, this facility was 
the site of 4623 injection events by about 120 people, with six overdoses that were 
successfully revived by the staff through the use of naloxone. Not much more is known 
about this facility due to its role as an unsanctioned SIF, however one study was able to 
interview individuals involved in this site (Davidson, Lopez, & Kral, 2018).  People who 
attended this SIF reported many positive health benefits, including less rushed injections, 
improved injection habits, and fewer public injections. The less public environment also 
helped to avoid the stress and stigma associated with their experiences injecting in public 
(Davidson, Lopez, & Kral, 2018).   
The positive benefits of the “underground” SIF match what is seen in legal SIFs 
like Insite. However, the illegal nature of this facility causes a few key differences 
(Davidson, Lopez, & Kral, 2018). In a way, the illegality is perceived to be beneficial 
because the SIF can focus on the needs of its community instead of following political 
concerns set by lawmakers. There is a feeling of ownership and control over this facility 
that the people fear would be lost if subject to governmental regulation. There are also 
several costs associated with being an illegal facility. First of all, the secrecy of the 
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facility must be maintained. An individual who is being loud or is fighting, is quickly 
ousted, and the number of people who can know about and access the facility has to be 
limited due to the risk of legal consequences if this facility became common knowledge. 
This unfortunately limits the extent to which the SIF can engage the PWID community 
and makes it harder to help the most at at-risk members of the community who lack the 
resources or connections to learn about this SIF. Furthermore, it is difficult to refer 
people to treatment or social services because of the need for the agency to keep a 
distance between the agency’s legal social service activities and its illegal SIF activities 
(Davidson, Lopez, & Kral, 2018). Although this facility is able to attract PWID and offer 
them several of the benefits that a sanctioned SIF can provide, a legal SIF would be better 
situated to have a wider and longer lasting impact on improving the lives of the people in 
its community. 
Medical organizations have also started to voice support of SIFs to combat the 
opioid crisis. In 2016, the Massachusetts Medical Society Task Force on Opioid Therapy 
and Physician Communication (Task Force) began to work on analyzing the costs, 
benefits, and feasibility of establishing a SIF in Massachusetts (“Establishment of a Pilot 
Medically Supervised Injection Facility in Massachusetts”, 2017). The Task Force 
examined the research conducted on SIFs, most of which came from a site in Australia 
and Insite in Canada. They complied an extensive report using SWOT analysis, a method 
to examine the strengths, weaknesses, opportunities, and threats that exist for a potential 
SIF (Figure 7). The resulting study made the recommendation that the Massachusetts 
Medical Society should advocate for a pilot supervised injection facility receiving 
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legalization from the state of Massachusetts and an exemption from federal drug laws. 
This facility should have an advisory board of experts to develop the protocols of 
evaluating the pilot SIF, possibly building on a previously established program like 
SPOT, and consider harm-reduction strategies as a component that goes beyond the SIF 
to engage marginalized PWID in health care. In April 2017, the Massachusetts Medical 
Society adopted these recommendations as official policy (“Establishment of a Pilot 
Medically Supervised Injection Facility in Massachusetts”). A few months later, these 
findings would assist the American Medical Association in their decision to also endorse 
the establishment of pilot SIF programs (“AMA Wants New Approaches to Combat 
Synthetic and Injectable Drugs,” 2017). The approval of SIFs by these major medical 
associations is a significant step forward in the push to establish a legal SIF in the United 
States. 
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Figure 7: Elements of a SWOT analysis used to evaluate a potential SIF program. The 
diagram explains the four main considerations explored by the Task Force established by 
the Massachusetts Medical Society to study the possibility of a Massachusetts SIF. SIF= 
medically supervised injection facility. Taken from (“Establishment of a Pilot Medically 
Supervised Injection Facility in Massachusetts,” 2017). 
 
A major stakeholder in the lobbying efforts toward establishing and supporting 
Insite was the Vancouver Area Network of Drug Users (VANDU). This organization was 
formed in response to the public health emergency declared by the Vancouver/Richmond 
Health Board in 1997 when confronted by outbreaks of blood-borne diseases, like HIV 
and HCV, as well as overdose fatalities that numbered over 300 per year. VANDU is run 
entirely by people who are currently engaged or were previously engaged in substance 
 38 
use. Although anyone is allowed to join VANDU, only people with a history of SUD can 
vote at meetings or be elected to the board (Kerr, Douglas, Peeace, Pierre, Wood, 2001). 
By placing these restrictions on decision making, VANDU protects it ability to represent 
the voice of the PWID community.  
During the early discussions in Vancouver over the establishment of a SIF and the 
strategy for harm reduction in general, VANDU made sure that they were a crucial part 
of the debate (Harati, 2015). Members organized to confront and challenge the stigma 
associated with injection drug use and invited government officials to meetings in order 
to share their concerns and discuss solutions. VANDU was also willing to lobby more 
aggressively for the sake of their population. For example, in 2001, then mayor of 
Vancouver, Phillip Owen, instituted a 90-day moratorium on new services for PWID 
while the government debated the issue. In response, VANDU presented Mayor Owen 
with a coffin and a check payable to the City of Vancouver for 90 human beings, 
representing the mortality rate of one person a day in the DTES. The moratorium lasted 
less than three weeks. Powerful lobbying such as this played a significant role in the 
eventual decision to establish Insite (Harati, 2015). As powerful as VANDU proved to be 
in the debate in Vancouver, as of now there is currently no group with a comparable 
presence that exists in Massachusetts (Doctor G. Wishik, personal communication, 
March 19, 2018). A PWID union within Massachusetts would be a critical tool in 
combating the stigma and emphasizing the humanity of this population.  
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Activists, medical professionals, and some lawmakers have been supportive of the 
establishment of a pilot SIF program in Massachusetts. However, this push has met 
resistance by those who are skeptical of such a program, most notable of whom is 
Massachusetts Governor Charlie Baker. He has stated that he does not believe that SIFs 
provide a viable path to treatment nor does he agree with the harm reduction argument. 
Furthermore, the mayors of Massachusetts’ two largest cities, Marty Walsh of Boston and 
Domenic Sarno of Springfield, are also opposed to SIFs, instead arguing the focus should 
be on treatment. (“Establishment of a Pilot Medically Supervised Injection Facility in 
Massachusetts”, 2017) Even if supporters are successful in gaining approval in 
Massachusetts, a pilot SIF could still be placed at risk if it cannot receive approval or an 
exemption by the federal government.  
The current political situation in Washington D.C. is not particularly favorable 
towards the possible approval of harm reduction methods. Attorney General Jeff Sessions 
has put an emphasis on investing in law enforcement to prosecute drug-related crimes 
without a similar commitment to encouraging harm reduction (“Attorney General Jeff 
Sessions Delivers Remarks Announcing New Tools to Combat the Opioid Crisis,” 2017). 
However, there is some evidence that politicians can change their opinions on harm 
reduction in the face of public health emergencies. Vice President Mike Pence eventually 
allowed needle exchanges to occur while he was the governor of Indiana, and in 2016 
Congress lifted a nearly three-decade-long ban on all funding of needle exchange 
programs (“Congress Ends Ban On Federal Funding for Needle Exchange Programs,” 
2016). This shows that while the current political environment might not be the most 
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conducive toward opening up an SIF, harm reduction methods can gain in popularity as 
people and politicians are confronted with the realities of the opioid crisis. Political 
concerns about SIFs often focus on the perceived impact that spending money on such a 
facility is funding that could have gone to treatment. Emphasizing the role that the SIF 
has played in Vancouver as a bridge to treatment could serve to alleviate those concerns.  
Even if Massachusetts legalizes the operation of an SIF, the facility would still be 
vulnerable to federal drug laws. Two sections of the federal Controlled Substances Act 
could be used to bar or interfere with the operations of a SIF. Section 844 prohibits drug 
possession, so this could be used to target anyone who uses the SIF. Section 856, also 
known as the Crack House Statute, makes it illegal to operate a place for the purpose of 
unlawfully using a controlled substance. Although federal law enforcement does not tend 
to target individuals, and there are some legal arguments that could be made that SIFs do 
not constitute as “crack houses,” the original target of Section 856, these laws still serve 
as points of vulnerability for a SIF. There is no guarantee that the federal courts would 
agree with such arguments defending SIFs (Beletsky, Davis, Anderson, & Burris, 2008).  
However, medical marijuana provides a precedent for the federal government 
allowing the use of illicit drugs as a form of medical intervention. Marijuana is officially 
classified as a Schedule I drug, much like heroin, under the federal Controlled Substances 
Act. Despite this, the Obama administration and Congress prevented any interference 
from the Department of Justice in the states that were implementing medical marijuana 
laws. The stance of the federal government allowed states to develop their own laws on 
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the matter, and by February 1, 2017, a total of 27 states and the District of Columbia had 
medical marijuana laws (Klieger et al., 2017).  
The current U.S. Attorney General Jeff Sessions has taken a much more 
aggressive stance toward enforcing federal marijuana laws. Regardless, Congress has 
recently added a provision to protect state medical marijuana laws from the Department 
of Justice, as a part of a key spending bill that will fund the federal government until 
September 30, 2018, the end of the Fiscal Year 2018. In addition, there is already a push 
by bipartisan group to include these protections in the Fiscal Year 2019 spending 
legislation (“Congress Protects Medical Marijuana from Jeff Sessions in New Federal 
Spending Bill”, 2018). The case of medical marijuana shows that the Department of 
Justice has very limited options when either Congress or the Presidency does not want 
them to target the actions of a state. Although the support of the executive and the 
legislative branches of the federal government would be ideal for developing a pilot SIF 
program, one of them would probably be able to give enough political and legal 
protection for the development of an SIF. Once Massachusetts agrees to develop an SIF, 
supporters of this program would then have to turn their efforts towards getting the 
approval of at least one of those branches.  
Police presence was one of the concerns that PWID had when deciding to use an 
SIF (Petrar et al., 2007). An aggressive police presence near the location of an SIF could 
intimidate people who would potentially benefit from the harm reduction services. 
Therefore, it is necessary to engage with the law enforcement community when 
 42 
developing plans for a SIF. Fortunately, there is already a recent history of the police in 
Massachusetts taking up harm reduction techniques.  
In 2010, the police department in Quincy, Massachusetts, a community of 92,000 
located south of Boston, became the first police department to be a part of the OEND 
program. In Quincy, the locally contracted ambulance service has only two stations, 
whereas the police officers are much more numerous and are dispatched to all 911 calls. 
Therefore, police officers have become an important resource of naloxone since they are 
usually the first to arrive at an overdose call. During the period 2010-2013, Quincy police 
administered naloxone 201 times (Davis, Ruiz, Glynn, Picariello, & Walley, 2014). The 
Quincy police chief has attributed this program to a sustained 45% decrease in the death 
rate in Quincy since the program went into effect. Furthermore, under “Good Samaritan” 
laws, the police in Quincy will seize and destroy drugs found at a scene of an overdose, 
but not arrest anyone who called the police to report an overdose (“Police Report 
Naloxone Highly Effective at Reducing Drug Deaths”, 2014). Police departments around 
the country are starting to focus more on helping people get into treatment rather than 
relying on purely punitive measures (Mankiewicz, Harpaz, Nguyen, & Schuppe, 2016). 
These efforts show that through working with the police it could be possible to not only 
reduce the chilling effect that law enforcement might have on PWID seeking harm 
reduction, but also serve as a powerful advocate for harm reduction as a whole. All 
efforts to establish an SIF in Massachusetts would benefit from engaging with law 
enforcement. 
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When the future site of an SIF is considered, the need to find a location that is 
convenient for the PWID population must also be balanced against the concerns of the 
local non-PWID community. A successful SIF attracts a significant number of PWID to 
the community, which is likely face resistance from the other inhabitants. To find out the 
opinions of the community of an SIF, SPOT conducted an online survey of individuals 
living within 500 meters of it location, both before and after the service was established, 
on their opinion on a SIF. Initially, 47.5% thought it was a good idea, and after SPOT 
opened, that number increased 50.4% (“Establishment of a Pilot Medically Supervised 
Injection Facility in Massachusetts,” 2017). This number still leaves about half of the 
population opposed to an SIF, and this value could increase if discussion of a SIF 
switches from a theoretical proposition to a concrete proposal. In addition, it is possible 
that these survey participants, who were inhabitants of the South End, an area with 
multiple substance use disorder treatment and care facilities, believed that they were 
already shouldering a large amount of the burden from the opioid crisis. Ultimately, any 
proposed SIF would likely need robust public support to gain approval; therefore, public 
outreach and education will be critical.  
Reducing stigmatizing language associated with SUD could play a major role in 
that way the public perceives any pilot SIF program. Even among medical professionals, 
language can affect how a patient is perceived. In one study, clinicians attending two 
mental health conferences were asked to read a short vignette describing an individual 
with a substance use disorder. These vignettes described the individual as either a 
“substance abuser” or a person with a “substance use disorder.” The clinicians were then 
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given a questionnaire in which they rated the level to which they agreed with statements 
about the patient. Among those who read about the “substance abuser” they were more 
likely to place blame on the patient and to agree that he should spend time in jail, than the 
patient with “substance use disorder. (Kelly & Westerhoff, 2010). Advocates of harm 
reduction must be careful to navigate the stigma associated with SUD. 
The term, “medically supervised injection facility,” is descriptive from a public 
health perspective; however, the term does not clearly establish the goal of harm 
reduction, but rather places focus on the act of injection. King County in Washington 
State, an area that is currently working to establish a SIF of their own, has named these 
proposed facilities Community Health Engagement Locations, or CHEL for short 
(“Heroin & Prescription Opiate Addiction Task Force: Frequently Asked Questions – 
King County,” 2017). This name does a better job of promoting the goal of harm 
reduction goal to the general public than simply calling it an SIF. Advocates for SIFs in 
Massachusetts would likely benefit from following the example set by King County and 
creating a name that focuses less on potentially inflammatory language and more on 
emphasizing harm reduction. 
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DISCUSSION 
 
 Substance use disorder is a major cause of mortality and morbidity in the United 
States and its negative impacts are only becoming more widespread. Massachusetts 
suffers from a rate of mortality due to this disease that is even greater than the national 
average. The emerging presence of potent illicit fentanyl and its analogues have played a 
significant role in this increase in mortality over the past few years. Although abstinence 
from substance use is the best way to prevent adverse outcomes, achieving this in the 
entire PWID community is not a realistic goal. For the people who are actively using, 
harm reductionists work to reduce the incidence and impact of disease and death.  
North America’s first legally sanctioned SIF, Insite, has demonstrated the power 
of such a facility to prevent adverse outcomes in the PWID community. Insite was 
opened to reduce injection-related harms that occurred in the DTES community of 
Vancouver, Canada, and has been successful in doing so. Medical interventions during 
overdoses that occurred at Insite have saved lives. The facility has also been successful in 
attracting people who would otherwise inject in public or engage in other high-risk 
injection habits. Insite has helped make the process of injecting substances safer, even 
when the act occurred outside the facility. Insite has also helped bring PWID, a medically 
underserved and marginalized community, in contact with medical professionals who 
have experience working with people with SUD. Through this engagement, Insite has 
been able to connect people to detox and treatment for their substance use disorder. 
Furthermore, Insite has been able to improve the health of the PWID community by 
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offering medical procedures and referrals as well as health counseling and education. 
Conversely, Insite has not been associated with the initiation of injection drug use nor is 
there any evidence to suggest that Insite has caused an increase in crime or injection-
related public nuisance. Overall, the research on Insite suggests that SIFs are a powerful 
tool to improve the health of the PWID community. 
While Insite has had a remarkable impact in Canada, there is currently no legally 
sanctioned SIF in the United States. However, based on the responses of participants of 
NEP in Boston and the usage of an illicit SIF located in the United States, there exists a 
demand for the benefits offered from such a facility. The Massachusetts Medical Society 
and the American Medical Association have both expressed interest in establishing a pilot 
program to determine feasibility and effectiveness of a SIF within the U.S. However, 
obstacles to such a program include the legality at the state and federal level, police 
response, and opposition from local communities. Despite the current barriers, the human 
toll of the opioid crisis is too heavy not to establish a SIF. In 2016, there was 2,155 
deaths due to opioid related overdoses in Massachusetts, with 246 of those occurring in 
Suffolk County, the county that is home to Boston. These numbers are more than double 
the amount that occurred just three years previously in 2013, when there were 961 and 
111 opioid related overdose deaths in Massachusetts and Suffolk County respectively 
(“Current opioid statistics,” 2018). As mentioned previously, the opening of Insite was 
associated with a 35% reduction of overdose related fatalities in the area of the facility. 
The area around Boston Medical Center, home to various addiction services, like SPOT, 
as well as a concentration of people with SUD, could provide a location that would allow 
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a SIF to engage with a large amount of PWID in Boston. If the assumption is made that a 
similar reduction could happen with a SIF located in Boston, this creates the possibility 
that in 2016, as many as 86 overdose fatalities could have been avoided due to the impact 
of the SIF. With the opioid crisis continuing the ravage our communities, it is necessary 
to use every lifesaving tool possible, especially one as potent as a SIF. 
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